Identification

Name
Indapamide
Accession Number
DB00808  (APRD01031)
Type
Small Molecule
Groups
Approved
Description

A benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]

Structure
Thumb
Synonyms
  • Indapamid
  • Indapamida
  • Indapamide
  • Indapamidum
  • Metindamide
External IDs
RHC 2555 / S 1520 / SE 1520 / USV 2555
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-indapamide Tablets 1.25mgTablet1.25 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Dom-indapamide Tablets 2.5mgTablet2.5 mgOralDominion Pharmacal1999-09-15Not applicableCanada
IndapamideTablet1.25 mgOralSanis Health Inc2015-10-14Not applicableCanada
IndapamideTablet2.5 mgOralSanis Health Inc2015-10-14Not applicableCanada
IndapamideTablet2.5 mgOralSanis Health IncNot applicableNot applicableCanada
Indapamide Hemihydrate 1.25mg - TabTablet1.25 mgOralProval Pharma Division Of Servier Canada Inc1997-08-142012-02-13Canada
Indapamide Hemihydrate Tab 2.5mgTablet2.5 mgOralProval Pharma Division Of Servier Canada Inc1995-12-312012-02-13Canada
Indapamide-2.5Tablet2.5 mgOralPro Doc Limitee1997-04-302008-07-04Canada
Jamp-indapamideTablet1.25 mgOralJamp Pharma Corporation2011-10-17Not applicableCanada
Jamp-indapamideTablet2.5 mgOralJamp Pharma Corporation2011-10-17Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-indapamide 1.25 Mg TabletsTablet1.25 mgOralApotex Corporation2002-11-08Not applicableCanada
Apo-indapamide 2.5mg TabletsTablet2.5 mgOralApotex Corporation1996-10-02Not applicableCanada
IndapamideTablet, film coated1.25 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-07-122017-09-22Us
IndapamideTablet, film coated2.5 mg/1OralANI Pharmaceuticals, Inc.2017-04-24Not applicableUs
IndapamideTablet2.5 mg/1OralAmerigen Pharmaceuticals Inc.2016-10-06Not applicableUs
IndapamideTablet, film coated2.5 mg/1OralActavis Pharma Company2007-01-02Not applicableUs00228 2571 96 nlmimage10 f33df9af
IndapamideTablet, film coated1.25 mg/1OralANI Pharmaceuticals, Inc.2017-04-24Not applicableUs
IndapamideTablet, film coated2.5 mg/1OralAv Kare, Inc.2016-02-09Not applicableUs
IndapamideTablet, film coated2.5 mg/1OralMylan Pharmaceuticals1996-03-28Not applicableUs
IndapamideTablet2.5 mg/1OralRemedy Repack2010-09-162016-10-13Us
International/Other Brands
Arifon (Servier) / Bajaten (Merck) / Fludex (Servier) / Indamol (Teofarma) / Ipamix (Visufarma) / Lozide (Servier) / Lozol (sanofi-aventis) / Natrilix (Servier) / Natrix (Kyoto Yakuhin) / Noranat (Sandoz) / Tandix (Azevedos) / Tertensif (Servier) / Veroxil (Baldacci)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Arcosyl PlusIndapamide (1.25 mg) + Perindopril arginine (5.0 mg)TabletOralServierNot applicableNot applicableCanada
Arcosyl PlusIndapamide (2.5 mg) + Perindopril arginine (10.0 mg)TabletOralServierNot applicableNot applicableCanada
Arcosyl Plus LdIndapamide (0.625 mg) + Perindopril arginine (2.5 mg)TabletOralServierNot applicableNot applicableCanada
Coversyl PlusIndapamide (1.25 mg) + Perindopril erbumine (8 mg)TabletOralServierNot applicableNot applicableCanada
Coversyl PlusIndapamide (1.25 mg) + Perindopril erbumine (4 mg)TabletOralServier2002-12-19Not applicableCanada
Coversyl Plus HdIndapamide (2.5 mg) + Perindopril erbumine (8.0 mg)TabletOralServier2009-05-07Not applicableCanada
Coversyl Plus LdIndapamide (0.625 mg) + Perindopril erbumine (2 mg)TabletOralServier2003-05-16Not applicableCanada
Categories
UNII
F089I0511L
CAS number
26807-65-8
Weight
Average: 365.835
Monoisotopic: 365.06008979
Chemical Formula
C16H16ClN3O3S
InChI Key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
IUPAC Name
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide
SMILES
CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O

Pharmacology

Indication

For the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.

Structured Indications
Pharmacodynamics

Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide bears a structural similarity to the triazide diuretics which are known to decrease vascular smooth muscle reactivity. However, it differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. Indapamide appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. This same effect may cause hypokalcemia in susceptible individuals. Indapamide has also been shown to cause uterine myometrial relaxation in experimental animals. Overall, indapamide has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.

Mechanism of action

Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2.

TargetActionsOrganism
APotassium voltage-gated channel subfamily KQT member 1
inhibitor
Human
APotassium voltage-gated channel subfamily E member 1
inhibitor
Human
Absorption

Rapidly absorbed from gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

71-79%

Metabolism

Primarily hepatic. Indapamide is an extensively metabolized drug with only about 7+ACU- of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

Route of elimination

Indapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

Half life

14 hours (biphasic)

Clearance
Not Available
Toxicity

Side effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Indapamide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Indapamide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Indapamide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indapamide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Indapamide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Indapamide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Indapamide.Experimental, Investigational
AlaproclateAlaproclate may increase the hyponatremic activities of Indapamide.Experimental
AlclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Indapamide.Approved
AlcuroniumThe serum concentration of Indapamide can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Indapamide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Indapamide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Indapamide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Indapamide is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Indapamide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Indapamide.Approved
AlminoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Indapamide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Indapamide.Illicit
AlprenololIndapamide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanIndapamide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Indapamide.Approved
AmifostineIndapamide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Indapamide.Approved
AmiodaroneThe metabolism of Indapamide can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Indapamide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indapamide.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Indapamide is combined with Amyl Nitrite.Approved
AnagrelideIndapamide may increase the QTc-prolonging activities of Anagrelide.Approved
AndrographolideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Indapamide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Indapamide.Investigational
AnisodamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Indapamide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Indapamide can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Indapamide.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Indapamide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Indapamide can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Indapamide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Indapamide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Indapamide.Approved, Investigational
Arsenic trioxideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIndapamide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIndapamide may increase the QTc-prolonging activities of Asenapine.Approved
AtamestaneAtamestane may increase the hypokalemic activities of Indapamide.Investigational
AtazanavirThe metabolism of Indapamide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Indapamide.Approved
AtomoxetineThe metabolism of Indapamide can be decreased when combined with Atomoxetine.Approved
AtracuriumThe serum concentration of Indapamide can be increased when it is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Indapamide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil.Approved
AzithromycinIndapamide may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Indapamide.Investigational
BalsalazideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Indapamide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Indapamide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Indapamide.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.Approved, Investigational
BedaquilineIndapamide may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Indapamide.Investigational
BenactyzineThe serum concentration of Indapamide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Indapamide.Approved, Investigational
BendazacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Indapamide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Indapamide.Withdrawn
BenorilateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Indapamide can be increased when it is combined with Benzatropine.Approved
BepridilIndapamide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Indapamide.Approved
BethanidineBethanidine may increase the hypotensive activities of Indapamide.Approved
BevoniumThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Indapamide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Indapamide.Experimental
BimatoprostIndapamide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Indapamide can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Indapamide.Approved
BoceprevirThe metabolism of Indapamide can be decreased when combined with Boceprevir.Approved, Withdrawn
BornaprineThe serum concentration of Indapamide can be increased when it is combined with Bornaprine.Experimental
BortezomibThe metabolism of Indapamide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Indapamide can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123Indapamide may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Indapamide is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Indapamide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Indapamide.Experimental
BromfenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indapamide.Approved, Investigational
BucillamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Indapamide.Approved
BufexamacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Indapamide.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indapamide.Approved, Investigational
BupranololIndapamide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Indapamide.Experimental
CafedrineIndapamide may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolIndapamide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolIndapamide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumIndapamide may decrease the excretion rate of Calcium which could result in a higher serum level.Approved, Nutraceutical
Calcium AcetateIndapamide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateIndapamide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateIndapamide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateIndapamide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateIndapamide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateIndapamide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateIndapamide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateIndapamide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateIndapamide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateIndapamide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateIndapamide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Indapamide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Indapamide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indapamide.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Indapamide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Indapamide.Illicit, Investigational, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Indapamide.Withdrawn
CarprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Indapamide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Indapamide is combined with Carvedilol.Approved, Investigational
CaseinIndapamide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Indapamide.Approved, Investigational
CeritinibThe serum concentration of Indapamide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Indapamide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineIndapamide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Indapamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Indapamide.Approved, Investigational
CicletanineIndapamide may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Indapamide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Indapamide.Approved, Investigational
CiprofloxacinIndapamide may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIndapamide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIndapamide may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Indapamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Indapamide can be decreased when combined with Clemastine.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Indapamide.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Indapamide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Indapamide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Indapamide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Indapamide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Indapamide.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indapamide.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indapamide.Approved
ClonixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Clonixin.Approved
CloranololIndapamide may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Indapamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineIndapamide may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Indapamide can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Indapamide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Indapamide can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Indapamide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Indapamide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Indapamide.Approved
CrizotinibIndapamide may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Indapamide.Approved
CurcuminThe therapeutic efficacy of Indapamide can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideIndapamide may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Indapamide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Indapamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Indapamide.Approved
CymarinThe risk or severity of adverse effects can be increased when Indapamide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Indapamide can be decreased when used in combination with D-Limonene.Investigational
DabrafenibThe serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Indapamide.Investigational
DarifenacinThe serum concentration of Indapamide can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe metabolism of Indapamide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Indapamide.Approved, Investigational
DeferasiroxThe serum concentration of Indapamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilIndapamide may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe metabolism of Indapamide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Indapamide.Investigational
DeserpidineIndapamide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indapamide.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Indapamide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Indapamide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Indapamide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Indapamide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Indapamide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Indapamide.Vet Approved
DexetimideThe serum concentration of Indapamide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indapamide.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Indapamide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Indapamide.Approved, Investigational
DiazoxideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineIndapamide may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Indapamide.Approved
DiflunisalThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Indapamide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Indapamide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Indapamide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.Approved, Illicit
DihydroergotamineThe metabolism of Indapamide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Indapamide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.Experimental, Illicit
DihydrotachysterolIndapamide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Indapamide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indapamide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Indapamide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole.Approved
DisopyramideIndapamide may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Indapamide.Approved
DofetilideIndapamide may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronIndapamide may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneIndapamide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideIndapamide may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide.Approved
DoxercalciferolIndapamide may increase the hypercalcemic activities of Doxercalciferol.Approved
DoxycyclineThe metabolism of Indapamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Indapamide.Investigational
DronedaroneIndapamide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIndapamide may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Indapamide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.Approved
DuloxetineIndapamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Indapamide can be decreased when used in combination with E-6201.Investigational
EfonidipineIndapamide may increase the hypotensive activities of Efonidipine.Approved
EliglustatIndapamide may increase the QTc-prolonging activities of Eliglustat.Approved
EmeproniumThe serum concentration of Indapamide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Indapamide.Approved, Vet Approved
EnalaprilatIndapamide may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Indapamide.Experimental
EnzalutamideThe serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.Approved
EpanololIndapamide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Indapamide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Indapamide.Approved
EpoprostenolIndapamide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Indapamide.Experimental
EquilinEquilin may increase the hypokalemic activities of Indapamide.Approved
ErgocalciferolIndapamide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
ErythromycinIndapamide may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramIndapamide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide.Approved
EstroneEstrone may increase the hypokalemic activities of Indapamide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Indapamide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Indapamide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Indapamide.Approved
EthenzamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Indapamide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Indapamide.Approved, Illicit
EtodolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the hyponatremic activities of Indapamide.Withdrawn
EtoricoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Indapamide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Indapamide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Indapamide.Approved, Investigational
exisulindThe therapeutic efficacy of Indapamide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Indapamide.Approved
FenoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Indapamide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indapamide.Approved, Investigational
FlecainideIndapamide may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Indapamide.Investigational
FluconazoleThe metabolism of Indapamide can be decreased when combined with Fluconazole.Approved
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Indapamide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Indapamide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Indapamide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Indapamide.Approved
FluoxetineIndapamide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIndapamide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneFluprednidene may increase the hypokalemic activities of Indapamide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Indapamide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Indapamide.Approved
FlurbiprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineThe metabolism of Indapamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Indapamide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
FosamprenavirThe metabolism of Indapamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Indapamide can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indapamide.Approved
FosphenytoinThe metabolism of Indapamide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Indapamide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Indapamide can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidIndapamide may increase the QTc-prolonging activities of Gadobenic acid.Approved
GallamineThe serum concentration of Indapamide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Indapamide can be increased when it is combined with Gallamine Triethiodide.Approved
GemifloxacinIndapamide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateThe risk or severity of adverse effects can be increased when Indapamide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.Approved
GlycopyrroniumThe serum concentration of Indapamide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinIndapamide may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronIndapamide may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuacetisalThe therapeutic efficacy of Indapamide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Indapamide.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Indapamide.Approved
GuanazodineIndapamide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Indapamide.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Indapamide is combined with Guanfacine.Approved, Investigational
GuanoclorIndapamide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIndapamide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIndapamide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Indapamide.Investigational
HaloperidolIndapamide may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indapamide.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Indapamide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Indapamide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Indapamide.Approved, Illicit, Investigational
HexamethoniumThe serum concentration of Indapamide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
HigenamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Indapamide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Indapamide.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Indapamide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.Approved, Illicit
HyoscyamineThe serum concentration of Indapamide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuproxam.Withdrawn
IbutilideIndapamide may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe therapeutic efficacy of Indapamide can be decreased when used in combination with Icatibant.Approved
IdelalisibThe serum concentration of Indapamide can be increased when it is combined with Idelalisib.Approved
IloperidoneIndapamide may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Indapamide.Approved, Investigational
ImatinibThe metabolism of Indapamide can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Indapamide.Investigational
Imidazole salicylateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indapamide.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Indapamide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Indapamide.Investigational, Withdrawn
IndenololIndapamide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Indapamide can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Indapamide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Indapamide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Indapamide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Indapamide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indapamide.Approved
Ipratropium bromideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Indapamide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Indapamide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Indapamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Indapamide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Indapamide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Indapamide.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Indapamide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Indapamide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Indapamide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Indapamide.Investigational
ItraconazoleThe metabolism of Indapamide can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIndapamide may increase the arrhythmogenic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Indapamide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Indapamide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Indapamide.Approved, Investigational
KetoconazoleThe metabolism of Indapamide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Indapamide.Approved
LacidipineIndapamide may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Indapamide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Indapamide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Leflunomide.Approved, Investigational
LenvatinibIndapamide may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Indapamide.Approved, Investigational
LeuprolideIndapamide may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Indapamide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Indapamide.Approved, Investigational
LevodopaIndapamide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinIndapamide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indapamide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Indapamide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Indapamide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Indapamide.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Indapamide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.Approved
LinsidomineIndapamide may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Indapamide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indapamide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lisofylline.Investigational
LithiumIndapamide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Indapamide.Illicit
LofexidineIndapamide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lonazolac.Experimental
LopinavirThe metabolism of Indapamide can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Indapamide.Approved
LovastatinThe metabolism of Indapamide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Indapamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Indapamide can be increased when combined with Lumacaftor.Approved
LumefantrineIndapamide may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanIndapamide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineIndapamide may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Masoprocol.Approved, Investigational
MazaticolThe serum concentration of Indapamide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Indapamide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Indapamide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Indapamide.Approved
Mefenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Indapamide.Vet Approved
MeloxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Indapamide.Experimental
MesalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Indapamide.Approved, Illicit
MethanthelineThe serum concentration of Indapamide can be increased when it is combined with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Indapamide.Approved
MethoserpidineIndapamide may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Indapamide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Indapamide.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indapamide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Indapamide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Indapamide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Indapamide.Approved, Investigational
MetyrosineIndapamide may increase the hypotensive activities of Metyrosine.Approved
MibefradilIndapamide may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MifepristoneMifepristone may increase the QTc-prolonging activities of Indapamide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Indapamide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Indapamide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Indapamide.Approved
MinaprineMinaprine may increase the hypotensive activities of Indapamide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Indapamide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Indapamide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Indapamide.Approved, Investigational
MitotaneThe serum concentration of Indapamide can be decreased when it is combined with Mitotane.Approved
MizoribineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Indapamide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Indapamide.Approved
MofebutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Indapamide.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.Approved, Investigational
MoxifloxacinIndapamide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Indapamide.Approved, Investigational
MuzolimineIndapamide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Indapamide.Approved, Investigational
NabumetoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Indapamide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naftifine.Approved
NaftopidilIndapamide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.Approved
NaproxenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Indapamide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Indapamide.Investigational
NebivololThe risk or severity of adverse effects can be increased when Indapamide is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Indapamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Indapamide can be decreased when combined with Nelfinavir.Approved
NepafenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Indapamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Indapamide can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Indapamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Indapamide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Indapamide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Indapamide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineIndapamide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibIndapamide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineIndapamide may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Indapamide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Indapamide.Approved
NitrendipineIndapamide may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Indapamide.Approved
NitroaspirinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Indapamide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Indapamide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Indapamide.Approved, Illicit
ObinutuzumabIndapamide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Indapamide.Withdrawn
OfloxacinIndapamide may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Indapamide can be decreased when combined with Olaparib.Approved
OleandrinThe risk or severity of adverse effects can be increased when Indapamide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Indapamide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indapamide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Indapamide.Approved
OlopatadineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatIndapamide may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronIndapamide may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Indapamide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Indapamide.Approved
OrgoteinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Indapamide can be increased when it is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Indapamide can be increased when it is combined with Osimertinib.Approved
OtiloniumThe serum concentration of Indapamide can be increased when it is combined with Otilonium.Experimental, Investigational
OuabainThe risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Indapamide can be increased when it is combined with Oxitropium.Investigational
OxprenololIndapamide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenoniumThe serum concentration of Indapamide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Indapamide.Approved, Vet Approved
PalbociclibThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.Approved
PaliperidoneIndapamide may increase the QTc-prolonging activities of Paliperidone.Approved
PancuroniumThe serum concentration of Indapamide can be increased when it is combined with Pancuronium.Approved
PanobinostatIndapamide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Indapamide.Approved
ParecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Indapamide.Approved
ParicalcitolIndapamide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Indapamide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parthenolide.Investigational
PazopanibIndapamide may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Indapamide is combined with Penbutolol.Approved, Investigational
PentamidineIndapamide may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.Approved, Vet Approved
PentobarbitalThe metabolism of Indapamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe serum concentration of Indapamide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indapamide.Approved, Investigational
PerflutrenIndapamide may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Indapamide.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Indapamide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Indapamide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Indapamide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Indapamide.Approved, Investigational, Withdrawn
PhenglutarimideThe serum concentration of Indapamide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Indapamide.Withdrawn
PhenobarbitalThe metabolism of Indapamide can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Indapamide.Experimental
PhenoxybenzamineIndapamide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Indapamide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Indapamide.Approved
PhenylbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Indapamide.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Indapamide can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PimozideIndapamide may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Indapamide.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Indapamide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indapamide.Approved, Investigational
PipecuroniumThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Indapamide.Approved
PirenzepineThe serum concentration of Indapamide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Indapamide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Indapamide.Approved
PiroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Indapamide.Withdrawn
PolythiazideIndapamide may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Indapamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Indapamide.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Indapamide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Indapamide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Indapamide.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Indapamide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Indapamide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Indapamide.Experimental, Investigational
PrimaquineIndapamide may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Indapamide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideIndapamide may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
ProcyclidineThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Proglumetacin.Experimental
PromazineIndapamide may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropafenoneIndapamide may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe serum concentration of Indapamide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Indapamide can be increased when it is combined with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Indapamide.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Indapamide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Indapamide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Indapamide can be decreased when used in combination with PTC299.Investigational
QuetiapineIndapamide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Quinapril.Approved, Investigational
QuinidineIndapamide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIndapamide may increase the QTc-prolonging activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Indapamide.Approved
RanolazineThe metabolism of Indapamide can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Indapamide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.Approved
RemikirenRemikiren may increase the hypotensive activities of Indapamide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.Approved, Investigational
RescinnamineIndapamide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indapamide.Approved, Investigational
ResveratrolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RifabutinThe metabolism of Indapamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Indapamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Indapamide can be increased when combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Indapamide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Indapamide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Indapamide is combined with Riociguat.Approved
RisperidoneIndapamide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Indapamide.Approved, Investigational
RitonavirThe metabolism of Indapamide can be decreased when combined with Ritonavir.Approved, Investigational
RituximabIndapamide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indapamide.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indapamide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Indapamide.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Indapamide.Approved
SafrazineSafrazine may increase the hypotensive activities of Indapamide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Indapamide.Approved
SalsalateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.Approved
SaprisartanIndapamide may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Indapamide can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Indapamide.Approved
ScopolamineThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Indapamide.Approved, Investigational, Vet Approved
SelexipagIndapamide may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Indapamide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Indapamide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Indapamide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indapamide.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
SiltuximabThe serum concentration of Indapamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Indapamide can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide.Approved, Investigational
SitaxentanIndapamide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Indapamide.Approved
Sodium phosphateIndapamide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Indapamide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Indapamide.Investigational
SotalolIndapamide may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilIndapamide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide.Approved
SRT501The therapeutic efficacy of Indapamide can be decreased when used in combination with SRT501.Investigational
St. John's WortThe serum concentration of Indapamide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Indapamide can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleIndapamide may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
TalinololIndapamide may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Indapamide.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Indapamide.Approved
TarenflurbilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tarenflurbil.Investigational
TelaprevirThe metabolism of Indapamide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinIndapamide may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Indapamide can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Telmisartan.Approved, Investigational
TemocaprilIndapamide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Indapamide.Approved
TeriflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinIndapamide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineIndapamide may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetrahydropalmatineIndapamide may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Indapamide.Approved, Investigational, Withdrawn
TheodrenalineIndapamide may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
ThioridazineIndapamide may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneIndapamide may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Indapamide can be decreased when combined with Ticlopidine.Approved
TicrynafenIndapamide may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Indapamide.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Indapamide.Approved
TinoridineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Indapamide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Indapamide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.Approved
TocilizumabThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Indapamide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Indapamide.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.Approved
TolonidineIndapamide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Indapamide.Approved
TolterodineThe serum concentration of Indapamide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateIndapamide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Indapamide.Approved
ToremifeneIndapamide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indapamide.Approved
TranilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indapamide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Indapamide.Approved
TravoprostTravoprost may increase the hypotensive activities of Indapamide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Indapamide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Indapamide.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.Approved
TribenosideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideIndapamide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Indapamide.Experimental
TrimethaphanThe serum concentration of Indapamide can be increased when it is combined with Trimethaphan.Approved, Investigational
TriptolideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Indapamide.Investigational, Withdrawn
TropatepineThe serum concentration of Indapamide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Indapamide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Indapamide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Indapamide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
UnoprostoneIndapamide may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Indapamide.Investigational
ValdecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide.Approved, Investigational
VandetanibIndapamide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Indapamide.Approved
VecuroniumThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.Approved
VemurafenibIndapamide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Indapamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Indapamide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.Approved, Investigational
VincamineIndapamide may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIndapamide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Indapamide.Approved, Investigational
VoriconazoleThe metabolism of Indapamide can be decreased when combined with Voriconazole.Approved, Investigational
XipamideIndapamide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineIndapamide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Indapamide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Indapamide.Withdrawn
ZiprasidoneIndapamide may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilIndapamide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Magnesium, potassium and zinc needs increased.

References

Synthesis Reference

Chunyi Yeh, Yi-Lung Wang, Ya-Sheng Yang, Ya-Ching Chang Chein, "Oral sustained-release pharmaceutical composition of indapamide, production and use thereof." U.S. Patent US20060182803, issued August 17, 2006.

US20060182803
General References
  1. Dong DL, Wang QH, Yue P, Jiao JD, Gu RM, Yang BF: Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. Epub 2006 Mar 2. [PubMed:16556441]
External Links
Human Metabolome Database
HMDB14946
KEGG Drug
D00345
PubChem Compound
3702
PubChem Substance
46508626
ChemSpider
3574
BindingDB
25901
ChEBI
5893
ChEMBL
CHEMBL406
Therapeutic Targets Database
DAP000498
PharmGKB
PA449975
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Indapamide
ATC Codes
C03BA11 — IndapamideC09BX01 — Perindopril, amlodipine and indapamideG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 40:28.24 — Thiazide-like Diuretics
FDA label
Download (322 KB)
MSDS
Download (72.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentCalcium Phosphate Kidney Stones1
3Not Yet RecruitingTreatmentHypertensive1
4CompletedTreatmentHypertensive2
4CompletedTreatmentHypertensive / Impaired Renal Function1
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4Not Yet RecruitingTreatmentArterial Hypertension2
4RecruitingPreventionAcute Intracerebral Haemorrhage (ICH)1
Not AvailableRecruitingDiagnosticArterial Hypertension1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Cadista pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral1.25 mg/1
TabletOral2.5 mg/1
Tablet, film coatedOral1.25 mg/1
Tablet, film coatedOral2.5 mg/1
TabletOral2.5 mg
TabletOral1.25 mg
Prices
Unit descriptionCostUnit
Indapamide 2.5 mg tablet0.85USD tablet
Indapamide 1.25 mg tablet0.69USD tablet
Lozide 2.5 mg Tablet0.55USD tablet
Apo-Indapamide 2.5 mg Tablet0.31USD tablet
Mylan-Indapamide 2.5 mg Tablet0.31USD tablet
Novo-Indapamide 2.5 mg Tablet0.31USD tablet
Nu-Indapamide 2.5 mg Tablet0.31USD tablet
Pms-Indapamide 2.5 mg Tablet0.31USD tablet
Apo-Indapamide 1.25 mg Tablet0.2USD tablet
Mylan-Indapamide 1.25 mg Tablet0.2USD tablet
Pms-Indapamide 1.25 mg Tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)160-162U.S.Patent 3,565,911.
water solubility75 mg/LNot Available
logP2.2Not Available
pKa8.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0342 mg/mLALOGPS
logP2.52ALOGPS
logP2.64ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.85ChemAxon
pKa (Strongest Basic)0.097ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.31 m3·mol-1ChemAxon
Polarizability36.34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8868
Caco-2 permeable-0.5529
P-glycoprotein substrateNon-substrate0.6859
P-glycoprotein inhibitor INon-inhibitor0.9158
P-glycoprotein inhibitor IINon-inhibitor0.9179
Renal organic cation transporterNon-inhibitor0.8575
CYP450 2C9 substrateNon-substrate0.5265
CYP450 2D6 substrateNon-substrate0.7924
CYP450 3A4 substrateNon-substrate0.519
CYP450 1A2 substrateInhibitor0.582
CYP450 2C9 inhibitorNon-inhibitor0.5775
CYP450 2D6 inhibitorNon-inhibitor0.8151
CYP450 2C19 inhibitorNon-inhibitor0.6572
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7471
Ames testNon AMES toxic0.6869
CarcinogenicityNon-carcinogens0.7674
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.0823 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.986
hERG inhibition (predictor II)Non-inhibitor0.8804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0009000000-ed04e0a5871badc8b166
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-1729000000-15aecb441ef4febfe526
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-2910000000-b72aeba8db62ebdf9c17
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004r-6900000000-f819fedd1ac654d46dd4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9300000000-164a2972880c967d2195
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9100000000-d18afa355f919614b652
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01t9-9000000000-9d9e98925e9105738992
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03fr-9000000000-5e7568f4efd1730f47b9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-9000000000-ecfffadaaa03b447eaf5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0904000000-530b78f6cae834e11768
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-235673a939e2e7d8c5e3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0159-0900000000-a843660d42ffb01666fe
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0900000000-cfee205b361c580e3631
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00lr-0900000000-a6d8ff4d769ea09e8073
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0901000000-a76c5fd366807c180552
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0900000000-574a71dcc7f0b3f74693
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1900000000-ab046a8849c404d9b308
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00l6-4900000000-93f1cc6465f329fd111e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-8900000000-0e98ece38603802699f7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-9600000000-c7e6e85faab95871c46d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-9300000000-d9a4af4e617331f29e98
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-9100000000-60cb951d344ed0385fc6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014u-9000000000-d07d645a1ccd383e7a1b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-1900000000-861314def0ccc019ac04
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-2900000000-10b16fdb4047a076cc32

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
4-halobenzoic acids and derivatives / Benzenesulfonyl compounds / Indoles and derivatives / Benzoyl derivatives / Chlorobenzenes / Organosulfonamides / Aryl chlorides / Aminosulfonyl compounds / Carboxylic acid hydrazides / Azacyclic compounds
show 6 more
Substituents
Benzenesulfonamide / Halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Benzoic acid or derivatives / Benzenesulfonyl group / Indole or derivatives / Benzoyl / Chlorobenzene / Halobenzene / Aryl chloride
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, organochlorine compound, indoles (CHEBI:5893)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modul...
Gene Name
KCNQ1
Uniprot ID
P51787
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 1
Molecular Weight
74697.925 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849]
  2. Li RA, Miake J, Hoppe UC, Johns DC, Marban E, Nuss HB: Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes. J Physiol. 2001 May 15;533(Pt 1):127-33. [PubMed:11351021]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Telethonin binding
Specific Function
Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel...
Gene Name
KCNE1
Uniprot ID
P15382
Uniprot Name
Potassium voltage-gated channel subfamily E member 1
Molecular Weight
14674.66 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS: Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84. doi: 10.1124/dmd.108.022707. Epub 2008 Dec 12. [PubMed:19074530]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49